Assignee
ELANCO US INC
US·40 granted patents·36 pending applications·19 citations·filing 2014–2025
Top patents by PatentIndex Score
76 records- 0191US2026092107A1Anti-il31 antibodies for veterinary useELANCO US INC·Filed 2025·Application pending·0 cites
- 0288US10941206B2Chimeric canine anti-CD20 antibodyELANCO US INC·Filed 2019·Granted Mar 9, 2021·2 cites·4 claims
- 0387US10000811B2Markers to predict macrocyclic lactone drug resistance in dirofilaria immitis, the causative agent of heartworm diseaseELANCO US INC·Filed 2014·Granted Jun 19, 2018·6 cites·5 claims
- 0485US12448438B2Anti-IL31 antibodies for veterinary useELANCO US INC·Filed 2023·Granted Oct 21, 2025·0 cites·29 claims
- 0585US12435132B2Anti-IL31 antibodies for veterinary useELANCO US INC·Filed 2023·Granted Oct 7, 2025·0 cites·17 claims
- 0685US10519244B2Chimeric canine anti-CD20 antibodyELANCO US INC·Filed 2017·Granted Dec 31, 2019·4 cites·10 claims
- 0784US12121043B2Feed additive compositionsELANCO US INC·Filed 2023·Granted Oct 22, 2024·0 cites·14 claims
- 0883US12195548B2Chimeric canine anti-CD20 antibodyELANCO US INC·Filed 2023·Granted Jan 14, 2025·0 cites·7 claims
- 0981US11344047B2Methods and formulations for reducing bovine emissionsELANCO US INC·Filed 2016·Granted May 31, 2022·2 cites·20 claims
- 1077US12391991B2Markers to predict macrocyclic lactone drug resistance in Dirofilaria immitis, the causative agent of heartworm diseaseELANCO US INC·Filed 2022·Granted Aug 19, 2025·0 cites·16 claims
- 1176US12161667B2Therapeutic clay compositions and methods of usingELANCO US INC·Filed 2023·Granted Dec 10, 2024·0 cites·20 claims
- 1276US10300126B2Porcine reproductive and respiratory syndrome vaccine virusELANCO US INC·Filed 2018·Granted May 28, 2019·1 cites·13 claims
- 1376US2025134960A1Formulations for bovine granulocyte colony stimulating factor and variants thereofELANCO US INC·Filed 2024·Application pending·0 cites
- 1475US12304903B2Process for making an isoxazoline compound and intermediate thereofELANCO US INC·Filed 2024·Granted May 20, 2025·0 cites·28 claims
- 1575US2024090533A1Methods and formulations for reducing bovine emissionsELANCO US INC·Filed 2023·Application pending·0 cites
- 1674US11864567B2Methods and formulations for reducing bovine emissionsELANCO US INC·Filed 2022·Granted Jan 9, 2024·0 cites·6 claims
- 1774US11638434B2Feed additive compositionsELANCO US INC·Filed 2018·Granted May 2, 2023·0 cites·31 claims
- 1874US10155035B2Porcine reproductive and respiratory syndrome vaccine virusELANCO US INC·Filed 2017·Granted Dec 18, 2018·1 cites·13 claims
- 1974US2025092115A1Igg fc variants for veterinary useELANCO US INC·Filed 2024·Application pending·0 cites
- 2073US12583917B2IL17A antibodies and antagonists for veterinary useELANCO US INC·Filed 2022·Granted Mar 24, 2026·0 cites·16 claims
- 2173US10471133B2Methods and compositions for reducing the environmental impact of animal wasteELANCO US INC·Filed 2018·Granted Nov 12, 2019·1 cites·16 claims
- 2272US10188725B2Hybrid core feline vaccinesELANCO US INC·Filed 2016·Granted Jan 29, 2019·1 cites·14 claims
- 2372US2021163618A1Chimeric canine anti-cd20 antibodyELANCO US INC·Filed 2021·Application pending·0 cites
- 2471US12138296B2Formulations for bovine granulocyte colony stimulating factor and variants thereofELANCO US INC·Filed 2022·Granted Nov 12, 2024·0 cites·14 claims
- 2571US2022265597A1Antiviral effects of narasin in swine feedELANCO US INC·Filed 2022·Application pending·0 cites
- 2670US12234239B2Crystalline forms of 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrileELANCO US INC·Filed 2022·Granted Feb 25, 2025·0 cites·33 claims
- 2769US2024270820A1Il4/il13 receptor molecule for veterinary useELANCO US INC·Filed 2024·Application pending·0 cites
- 2868US12286462B2Porcine G-CSF variants and their usesELANCO US INC·Filed 2023·Granted Apr 29, 2025·0 cites·20 claims
- 2968US2025057191A1Methods of improving the nutritional status of immune stressed animalsELANCO US INC·Filed 2022·Application pending·0 cites
- 3067US2024033287A1Antimicrobial clay compositions and methods of usingELANCO US INC·Filed 2023·Application pending·0 cites
- 3166US11414703B2Markers to predict macrocyclic lactone drug resistance in Dirofilaria immitis, the causative agent of heartworm diseaseELANCO US INC·Filed 2018·Granted Aug 16, 2022·0 cites·11 claims
- 3266US2025127876A1Porcine reproductive and respiratory syndrome vaccine virusELANCO US INC·Filed 2024·Application pending·0 cites
- 3365US2025281585A1Veterinary compositions of modified virus-like particles of cmv and il-1 beta mutein antigensELANCO US INC·Filed 2025·Application pending·0 cites
- 3465US2025281587A1Veterinary compositions of modified virus-like particles of cmv and feline il-1 beta mutein antigensELANCO US INC·Filed 2025·Application pending·0 cites
- 3565US2025281586A1Veterinary compositions of modified virus-like particles of cmv and canine il-1 beta mutein antigensELANCO US INC·Filed 2025·Application pending·0 cites
- 3664US11738045B2Therapeutic clay compositions and methods of usingELANCO US INC·Filed 2020·Granted Aug 29, 2023·0 cites·20 claims
- 3764US11548895B2Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrileELANCO US INC·Filed 2020·Granted Jan 10, 2023·0 cites·24 claims
- 3864US11439701B2Bovine respiratory disease vaccineELANCO US INC·Filed 2018·Granted Sep 13, 2022·1 cites·13 claims
- 3964US2025215009A1PROCESS FOR MAKING CRYSTALLINE 2-(3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-1-(CYCLOPROPYLSULFONYL)AZETIDIN-3-YL)ACETONITRILEELANCO US INC·Filed 2025·Application pending·0 cites
- 4061US12214032B2Porcine Reproductive and Respiratory Syndrome vaccine virusELANCO US INC·Filed 2019·Granted Feb 4, 2025·0 cites·20 claims
- 4160US2021177980A1Pegylated porcine interferon and methods of use thereofELANCO US INC·Filed 2021·Application pending·0 cites
- 4260US2023257370A1Process for making an isoxazoline compound and intermediate thereofELANCO US INC·Filed 2021·Application pending·0 cites
- 4359US12544336B2Palatable formulationsELANCO US INC·Filed 2021·Granted Feb 10, 2026·0 cites·17 claims
- 4459US2023404925A1Jak inhibitors having a specific particle size distributionELANCO US INC·Filed 2021·Application pending·0 cites
- 4559US2025195192A1Winged capsule devices and methodsELANCO US INC·Filed 2023·Application pending·0 cites
- 4659US2022142972A1Parasiticidal formulations and use thereofELANCO US INC·Filed 2019·Application pending·0 cites
- 4758US2023363412A1Microbial treatmentELANCO US INC·Filed 2020·Application pending·0 cites
- 4857US11578111B2Porcine G-CSF variants and their usesELANCO US INC·Filed 2018·Granted Feb 14, 2023·0 cites·20 claims
- 4957US2022088094A1Probiotic compositions comprising lactobacillus reuteri strains and methods of useELANCO US INC·Filed 2021·Application pending·0 cites
- 5056US2025345361A1Compositions and methods to improve calf growth and reduce incidence of scoursELANCO US INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 76 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ELANCO US INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →